SCHEMBL177887

SCHEMBL177887

CCCC[C@H](O)[C@@H](O)CO

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.52
CYP2D6 P10635 2/20 0.52
SPHK1 Q9NYA1 2/20 0.52
GMNN O75496 1/20 0.52
POLB P06746 1/20 0.52
THPO P40225 1/20 0.52
MTOR P42345 1/20 0.52
BLM P54132 1/20 0.52
KDM4E B2RXH2 1/20 0.52
TP53 P04637 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52
MAPT P10636 1/20 0.52
CETP P11597 1/20 0.52
HTT P42858 1/20 0.52
UBE2N P61088 1/20 0.52
ALDH1A1 P00352 2/20 0.50
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
ASAH1 Q13510 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12731069 1.00 LMNA (0.52) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL177886 1.00 LMNA (0.52) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL16653364 0.92 CYP2D6 (0.61) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL11159 0.92 CYP2D6 (0.61) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL5549292 0.92 CYP2D6 (0.61) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL12198626 0.92 CYP2D6 (0.61) LMNACYP2D6SPHK1GMNNPOLB
Bicarbonate SCHEMBL29012522 0.91 CYP2D6 (0.45) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL25243382 0.90 LMNA (0.65) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL1964037 0.90 LMNA (0.65) LMNACYP2D6SPHK1GMNNPOLB
SCHEMBL10571108 0.90 LMNA (0.65) LMNACYP2D6SPHK1GMNNPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 318 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250275536-A1 Antimicrobial Composition KAMER, Patrick (CH) 2025-09-04 US claimed
WO-2023213846-A1 ANTIMICROBIAL COMPOSITION KAMER PATRICK (CH) 2023-11-09 WO claimed
CN-116751553-A Double-component polyurethane sealant and application thereof in unmanned aerial vehicle field 东莞市博翔电子材料有限公司 2023-09-15 CN claimed
US-20060068390-A1 Dna amplification and sequencing in collapsible emulsions NUCLEICS PTY LTD. (AU) 2006-03-30 US claimed
EP-1069131-B1 Methods for separating particulate substrates from solution while minimizing particle loss QIAGEN GMBH (DE) 2006-03-15 EP claimed
US-20040171077-A1 Methods for separating particulate substrates from solution while minimizing particle loss LUBENOW HELGE (DE) 2004-09-02 US claimed
US-6723510-B2 ISOLATION OF MOLECULES OF INTEREST USING AFFINITY PARTICLES WHERE AT LEAST ONE STEP IN THE ISOLATION IS DONE IN THE PRESENCE OF A DETERGENT WHICH REDUCES LOSS OF PARTICLES AND ENHANCES YIELD OF THE MOLECULE OF INTEREST QIAGEN GMBH (DE) 2004-04-20 US claimed
WO-2003106678-A1 DNA AMPLIFICATION AND SEQUENCING IN COLLAPSIBLE EMULSIONS NUCLEICS PTY LTD (AU) 2003-12-24 WO claimed
US-20010014466-A1 Methods for separating particulate substrates from solution while minimizing particle loss LUBENOW HELGE (DE) 2001-08-16 US claimed
EP-1069131-A1 Methods for separating particulate substrates from solution while minimizing particle loss QIAGEN GmbH (DE) 2001-01-17 EP claimed
EP-4705420-A1 ELECTRIC VEHICLE FLUIDS Chevron Oronite Company LLC (US) 2026-03-11 EP disclosed
EP-4662319-A2 PERSONALIZED CRISPR PROFILING FOR CANCER Integrate Bioscience LLC (US) 2025-12-17 EP disclosed
US-20250275536-A1 Antimicrobial Composition KAMER, Patrick (CH) 2025-09-04 US disclosed
WO-2023213310-A9 CARBON CHAIN SUBSTANCE FOR REGULATING TRANSMEMBRANE TRANSPORT AND FLUIDITY OF CELL MEMBRANES, AND PREPARATION AND USE THEREOF 太阳雨林(北京)生物医药有限公司 2025-02-20 WO disclosed
EP-3926045-B1 MUTANT PROTEINS AND METHODS FOR SELECTING THEM NXERA PHARMA UK LTD (GB) 2025-01-01 EP disclosed
EP-0242380-A1 A PROCESS FOR PREPARING IMMUNOGENIC COMPLEX. MOREIN BROR 1987-10-28 EP disclosed
WO-1987002250-A1 A PROCESS FOR PREPARING IMMUNOGENIC COMPLEX MOREIN BROR 1987-04-23 WO disclosed
EP-0180564-A2 Immunogenic complex, a method for producing the same, and the use thereof as an immune stimulant, vaccines and reagents Morein, Bror (SE) 1986-05-07 EP disclosed
US-4578269-A Immunogenic protein or peptide complex, method or producing said complex and the use thereof as an immune stimulant and as a vaccine MOREIN BROR (SE) 1986-03-25 US disclosed
EP-0109942-A2 Immunogenic protein or peptide complex, method of producing said complex and the use thereof as an immune stimulant and as a vaccine Morein, Bror (SE) 1984-05-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250275536-A1 Antimicrobial Composition CUTA, POLR1C, PIK3C3 LMNA 2754/4885CYP2D6 2614/4885SPHK1 2428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.